ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis
- PMID: 15677531
- PMCID: PMC1770577
- DOI: 10.1136/jcp.2004.019588
ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis
Abstract
Renal stones have afflicted humans for millennia but there is still no solution to this problem. This review discusses the laboratory and metabolic aspects of the clinical management of patients with renal stones, both primary and secondary in origin. First, non-pharmacological interventions such as increased fluid intake, decreased protein consumption, dietary changes in sodium, calcium, oxalate, potassium, purine, vitamins, and essential fatty acids are considered. Then specific pharmacological treatment to modify urine calcium, oxalate, urate, citrate, and acidity are considered. Finally, more unusual types of stone are examined.
References
-
- Bihl G, Meyers A. Recurrent renal stone disease—advances in pathogenesis and clinical management. Lancet 2001;358:651–6. - PubMed
-
- Wilkinson H . Clinical investigation and management of patients with renal stones. Ann Clin Biochem 2001;38:180–7. - PubMed
-
- Pantonowitz D, Pollen J, Politzer WM. Urinary calculi. S Afr Med J 1973;43:128–31. - PubMed
-
- Meyers AM, Whalley N, Martins M. Diagnostic and therapeutic aspects of recurrent renal stones disease. African Journal of Neprology 1998;2:12–17.
-
- Daudon M, Donsimoni R, Hennequin C, et al. Sex- and age-related composition of 10617 calculi analysed by infrared spectroscopy. Urol Res 1995;23:319–26. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources